XenoTech LLC and Solvo Biotechnology have announced that they have formed a strategic partnership to distribute and represent Solvo’s Membrane Transporter Assay Products and Services in the US and Canada.
"With XenoTech’s established expertise in drug-drug interaction studies and our reputation for high-quality in vitro products, we see this partnership with Solvo as a key part of our strategic development," states Tom Zaleski, VP of Sales, Marketing and Customer Service at XenoTech.
"Transporters are proving to be the next frontier in drug development; the increase of transporter topics at scientific conferences and within scientific publications is evidence of their growing importance in developing new compounds."
"As a leading supplier of high-quality in vitro products and services, we feel a strong responsibility to incorporate this important next generation of in vitro tools to satisfy industry’s expanding research needs, and we look forward to advancing the transporter market to its full potential."
"By now, it is common knowledge among researchers that membrane transporters play a key role in the function of the blood-brain barrier (BBB), blood-CSF barrier, blood-testis barrier, intestinal epithelia (absorption), airway epithelia, liver epithelia and the kidney epithelia," explained Gábor Heltovics, Solvo’s Business Development Director.
"Solvo’s leading assay systems are designed to detect interaction of compounds with a wide array of membrane transporter proteins found at these vital pharmacological barriers."
"We are very excited about the opportunity to work with XenoTech as a strategic partner to combine the market leading strength of our products and services that will provide significant added value to our North American Customers."